SGLT2 inhibitors reduce hospitalisation for hea failure as demonstrated by multiple cardiovascular outcome trials of various SGLT2 inhibitors. They produce glycosuria and weight loss. SGLT2 is a high capacity low affinity transpoer in contrast to SGLT1. In kidneys, SGLT2 is present in the proximal pa of the tubules while SGLT1 is present more distally. The low amount of glucose remaining after transpo by the SGLT2 is conserved by SGLT1 located distally as it has high affinity for glucose compared to SGLT2, produce viual absence of glucose in urine.